Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MIND: Switching to Biktarvy in HIV with Neuropsychiatric Vulnerabilities
NCT05549180Phase 4Completed
- Sponsor
- Fundación SEIMC-GeSIDA
- Start
- Oct 2022
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of bictegravir + emtricitabine + tenofovir alafenamide in human immunodeficiency virus infection (HIV), sponsored by Fundación SEIMC-GeSIDA. Started Oct 2022; status: completed.
02
Drugs
bictegravir + emtricitabine + tenofovir alafenamide
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT05549180.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05549180.